Genetic Test Would Help Cut Bowel Cancer Spread
By LabMedica International staff writers Posted on 15 Oct 2014 |
Image: Histopathology of non-polyposis colorectal cancer or Lynch Syndrome (Photo courtesy of Dr. L. Marcucci MD).
Screening families of patients with bowel cancer for a genetic condition would cut their risk of developing bowel, womb, and ovarian cancers.
Lynch syndrome (LS) is an inherited autosomal dominant disorder characterized by an increased risk of colorectal cancer (CRC) and other cancers, and caused by mutations in the DNA mismatch repair genes.
Scientists at the University of Exeter Medical School (UK) and Cardiff University (UK) evaluated the accuracy and cost-effectiveness of strategies to identify LS in newly diagnosed early-onset CRC patients who were less than 50 years of age. Cascade testing of relatives is employed in all strategies for individuals in whom LS was identified. The investigators conducted systematic reviews of the test accuracy of microsatellite instability (MSI) testing or immunohistochemistry (IHC) in individuals with CRC at risk of LS, and of economic evidence relating to diagnostic strategies for LS.
The team identified and assessed 42 studies in total, before constructing a computer model of screening strategies for Lynch Syndrome. These were of mixed quality, with significant methodological concerns identified for most. IHC and MSI can both play a part in diagnosing LS but neither is gold standard. The maximum health benefit to the population of interest would be obtained using universal germline testing, but this would not be cost-effective.
The findings indicate that screening the 1,700 people under the age of 50 who are newly diagnosed with bowel cancer each year would identify two thirds of these whose cancer was caused by Lynch Syndrome. From this group, the findings suggest that 40 further cases of cancer could be avoided in them and their relatives. The team used the same model to estimate that 28 cancer related deaths, 24 from bowel cancer and four from womb cancer, could be prevented each year if Lynch Syndrome screening for people with bowel cancer was introduced.
Ian Frayling, PhD, MRCPath, a senior coauthor, said, “If Lynch Syndrome is identified as the cause of bowel cancer, patients can be offered risk-reducing measures such as more intensive postoperative colonoscopy surveillance to spot recurrences and new cancers early. As close relatives have a 50% chance of sharing the gene, screening would provide a valuable opportunity to detect the condition in children, siblings, parents and more distant relatives. It would mean measures could be taken to reduce the risk of cancers developing.” The study was published in the September 2014 issue of the journal Health Technology Assessment.
Related Links:
University of Exeter Medical School
Cardiff University
Lynch syndrome (LS) is an inherited autosomal dominant disorder characterized by an increased risk of colorectal cancer (CRC) and other cancers, and caused by mutations in the DNA mismatch repair genes.
Scientists at the University of Exeter Medical School (UK) and Cardiff University (UK) evaluated the accuracy and cost-effectiveness of strategies to identify LS in newly diagnosed early-onset CRC patients who were less than 50 years of age. Cascade testing of relatives is employed in all strategies for individuals in whom LS was identified. The investigators conducted systematic reviews of the test accuracy of microsatellite instability (MSI) testing or immunohistochemistry (IHC) in individuals with CRC at risk of LS, and of economic evidence relating to diagnostic strategies for LS.
The team identified and assessed 42 studies in total, before constructing a computer model of screening strategies for Lynch Syndrome. These were of mixed quality, with significant methodological concerns identified for most. IHC and MSI can both play a part in diagnosing LS but neither is gold standard. The maximum health benefit to the population of interest would be obtained using universal germline testing, but this would not be cost-effective.
The findings indicate that screening the 1,700 people under the age of 50 who are newly diagnosed with bowel cancer each year would identify two thirds of these whose cancer was caused by Lynch Syndrome. From this group, the findings suggest that 40 further cases of cancer could be avoided in them and their relatives. The team used the same model to estimate that 28 cancer related deaths, 24 from bowel cancer and four from womb cancer, could be prevented each year if Lynch Syndrome screening for people with bowel cancer was introduced.
Ian Frayling, PhD, MRCPath, a senior coauthor, said, “If Lynch Syndrome is identified as the cause of bowel cancer, patients can be offered risk-reducing measures such as more intensive postoperative colonoscopy surveillance to spot recurrences and new cancers early. As close relatives have a 50% chance of sharing the gene, screening would provide a valuable opportunity to detect the condition in children, siblings, parents and more distant relatives. It would mean measures could be taken to reduce the risk of cancers developing.” The study was published in the September 2014 issue of the journal Health Technology Assessment.
Related Links:
University of Exeter Medical School
Cardiff University
Latest Pathology News
- Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues
- New AI Tool Classifies Brain Tumors More Quickly and Accurately
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples